BOSTON--(BUSINESS WIRE)--Feb. 4, 2019--
Verastem, Inc. (Nasdaq:VSTM) (“Verastem Oncology” or “the Company”),
focused on developing and commercializing medicines to improve the
survival and quality of life of cancer patients, today announced the
grant of options to purchase 46,000 shares of its common stock to six
new employees. The awards were granted as an inducement material to the
employees' acceptance of employment with Verastem Oncology in accordance
with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price
equal to $3.22 per share, the closing price of Verastem Oncology's
common stock as reported by Nasdaq on February 1, 2019 and vest at a
rate of 25% on the one-year anniversary of his or her date of hire, and
thereafter, at a rate of 6.25% of the shares subject to the options at
the end of each successive three-month period, provided that the
employee continues to serve as an employee of or other service provider
to Verastem Oncology on each such vesting date.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005536/en/
Source: Verastem, Inc.
Senior Director, Investor
Relations and Corporate Communications